<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04992260</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-nCOV-3002</org_study_id>
    <nct_id>NCT04992260</nct_id>
  </id_info>
  <brief_title>Efficacy, Immunogenicity and Safety of COVID-19 Vaccine , Inactivated in Children and Adolescents</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Placebo-controlled Phase Ⅲ Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of COVID-19 Vaccine(Vero Cell) ,Inactivated in Children and Adolescents Aged 6 Months to 17 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sinovac Research and Development Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sinovac Biotech Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a global multi-center , case-driven, randomized, double-blinded, and&#xD;
      placebo-controlled phase Ⅲ clinical trial of the SARS-CoV-2 inactivated vaccine manufactured&#xD;
      by Sinovac Research &amp; Development Co., Ltd. The purpose of this study is to evaluate the&#xD;
      efficacy of two dose of CoronaVac® against RT-PCR confirmed symptomatic COVID-19 cases in&#xD;
      participants aged 6 months to 17 years.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a global multi-center , case-driven, randomized, double-blinded, and&#xD;
      placebo-controlled phase Ⅲ clinical trial in participants aged 6 months to 17 years.The&#xD;
      purpose of this study is to evaluate the efficacy of two dose of CoronaVac® against RT-PCR&#xD;
      confirmed symptomatic COVID-19 cases in participants aged 6 months to 17 years.The&#xD;
      experimental vaccine and placebo were both manufactured by Sinovac Research &amp; Development&#xD;
      Co., Ltd. A total of 14,000 healthy participants aged 6 months to 17 years will be enrolled,&#xD;
      and randomly assigned into 2 groups at a ratio of 1:1 to receive 2 doses of experimental&#xD;
      vaccine (600SU) or placebo with an interval of 28 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 25, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy index-incidence of RT-PCR confirmed symptomatic COVID-19 cases with onset</measure>
    <time_frame>14 days after the second dose</time_frame>
    <description>Incidence of RT-PCR confirmed symptomatic COVID-19 cases with onset at least 14 days after the second dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy index-incidence of RT-PCR confirmed symptomatic COVID-19 cases with onset</measure>
    <time_frame>14 days after the first dose</time_frame>
    <description>Incidence of RT-PCR confirmed symptomatic COVID-19 cases with onset at least 14 days after the first dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy index-incidence of RT-PCR confirmed, symptomatic COVID-19 cases with onset in SARS-CoV-2 uninfected participants</measure>
    <time_frame>14 days after the second dose</time_frame>
    <description>Incidence of RT-PCR confirmed, symptomatic COVID-19 with onset at least 14 days after the second dose in SARS-CoV-2 uninfected (serologically or molecularly confirmed) participants at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy index-incidence of hospitalization/severe/death caused by COVID-19 with onset</measure>
    <time_frame>14 days after the second dose</time_frame>
    <description>Incidence of hospitalization/severe/death caused by COVID-19 with onset at least 14 days after the second dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety index-occurrence, intensity, duration, and relationship of solicited local and systemic AEs and of unsolicited AEs</measure>
    <time_frame>During 7 days following each dose vaccination and during 28 days post-vaccination</time_frame>
    <description>Occurrence, intensity, duration, and relationship of solicited local and systemic AEs during 7 days following each dose vaccination and of unsolicited AEs during 28 days post-vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety index-occurrence and relationship of SAEs</measure>
    <time_frame>From first dose to 12 months after the last dose</time_frame>
    <description>Occurrence and relationship of SAEs from first dose to 12 months after the last dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety index-occurrence and relationship of AESI</measure>
    <time_frame>From first dose to 12 months after the last dose</time_frame>
    <description>Occurrence and relationship of AESI from first dose to 12 months after the last dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity index(subgroup)-SARS-CoV-2 neutralizing antibody titers</measure>
    <time_frame>From first dose to 12 months after the last dose</time_frame>
    <description>Analysis of SARS-CoV-2 neutralizing antibody titers by micro-cytopathic method to compare with the placebo group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity index(subgroup)-Anti-SARS-CoV-2 S</measure>
    <time_frame>From first dose to 12 months after the last dose</time_frame>
    <description>Analysis of Anti-SARS-CoV-2 S by electrochemiluminescence immunoassay to compare with the placebo group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">14000</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Experimental Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7000 subjects (including 100 participants aged 6-35 months ,1900 participants aged 3-5 years ,2500 participants aged 6-11 years and 2500 aged 12-17 years )will receive two doses of inactivated COVID-19 vaccine on day 0 and day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>7000 subjects (including 100 participants aged 6-35 months ,1900 participants aged 3-5 years ,2500 participants aged 6-11 years and 2500 aged 12-17 years )will receive two doses of placebo on day 0 and day 28.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Inactivated COVID-19 Vaccine</intervention_name>
    <description>The inactivated COVID-19 vaccine was manufactured by Sinovac Research&amp; Development Co., Ltd..600SU Inactivated SARS-COV-2 virus in 0·5 mL of aluminium hydroxide solution per injection</description>
    <arm_group_label>Experimental Group</arm_group_label>
    <other_name>CoronaVac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Controlled vaccine</intervention_name>
    <description>The placebo was manufactured by Sinovac Research&amp; Development Co., Ltd.The composition is aluminium hydroxide,The appearance of the placebo is consistent with the vaccine, which is a milky-white suspension.</description>
    <arm_group_label>Control Group</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy children and adolescents aged 6 months to 17 years;&#xD;
&#xD;
          -  The participants and/or their guardians are able to understand and sign the informed&#xD;
             consent voluntarily (in accordance with the local regulations);&#xD;
&#xD;
          -  Able to comply with study procedures based on the assessment of the Investigator;&#xD;
&#xD;
          -  Female participants of childbearing potential (post-menarche girls or in accordance&#xD;
             with the local standard of care) may be enrolled in the study if the participant&#xD;
             fulfills all the following criteria:&#xD;
&#xD;
               -  Has a negative pregnancy test on the day of the first dose (Day 0).&#xD;
&#xD;
               -  Has practiced adequate contraception or has abstained from all activities that&#xD;
                  could result in pregnancy for at least 28 days prior to the first dose (Day 0).&#xD;
&#xD;
               -  Has agreed to continue adequate contraception through 3 months following the&#xD;
                  second dose (Day 28).&#xD;
&#xD;
               -  Is not currently breastfeeding.&#xD;
&#xD;
          -  Must be willing to provide verifiable identification (in accordance with the local&#xD;
             regulations), has means to be contacted and to contact the investigator during the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of confirmed infection of SARS CoV-2 prior to randomization;&#xD;
&#xD;
          -  Close contact with a confirmed COVID-19 within 14 days prior to randomization;&#xD;
&#xD;
          -  Prior administration of an investigational coronavirus vaccine or current/planned&#xD;
             simultaneous participation in another interventional study to prevent or treat&#xD;
             COVID-19;&#xD;
&#xD;
          -  Allergy to vaccines or vaccine/placebo ingredients, and serious adverse reactions to&#xD;
             vaccines, such as urticaria, dyspnea, angioneuroedema;&#xD;
&#xD;
          -  Personal or first-grade relative (siblings) history of multisystem inflammatory&#xD;
             disease in children (MIS-C);&#xD;
&#xD;
          -  Significant chronic illnesses that, in the opinion of the investigator, is at a stage&#xD;
             where it might interfere with trial conduct or completion (may include, but are not&#xD;
             limited to cardiovascular disease, liver or kidney disorders, respiratory illnesses)&#xD;
&#xD;
          -  Significant chronic central nervous system diseases or neuromuscular disorders,&#xD;
             psychosis or severe cognitive behavioral disorder, in the opinion of the investigator,&#xD;
             including epilepsy, autism spectrum disorder, intellectual disabilities (excluding&#xD;
             Down Syndrome);&#xD;
&#xD;
          -  Acute central nervous system diseases such as encephalitis/myelitis, acute&#xD;
             disseminating encephalomyelitis, and related disorders;&#xD;
&#xD;
          -  History of autoimmune and/or haematological diseases (including but not limited to&#xD;
             systemic lupus erythematosus, thyroidectomy, autoimmune thyroid disease, any form of&#xD;
             malignant tumor, asplenia, functional asplenia, or splenectomy resulting from any&#xD;
             condition); well controlled type I diabetes mellitus is allowed;&#xD;
&#xD;
          -  History of bleeding disorders (e.g. factor deficiency, coagulopathy or platelet&#xD;
             disorder), or prior history of significant bleeding or bruising following IM&#xD;
             injections or venipuncture;&#xD;
&#xD;
          -  Immunosuppressive therapy (systemic corticoid therapy, e.g. prednisone ≥2 mg/Kg/d or&#xD;
             ≥20 mg/day for &gt;14 days), cytotoxic therapy (antineoplastic chemotherapy, radiation&#xD;
             therapy), (excluding topical or aerosol corticosteroid therapy) in the past 6 months;&#xD;
&#xD;
          -  Receipt of blood products or immunoglobulins in the past 3 months;&#xD;
&#xD;
          -  Receipt of other investigational drugs in the past 30 days;&#xD;
&#xD;
          -  Receipt of attenuated live vaccines in the past 14 days;&#xD;
&#xD;
          -  Receipt of inactivated or subunit vaccines in the past 7 days;&#xD;
&#xD;
          -  Acute exacerbation or presentation of stable chronic diseases (including but not&#xD;
             limited to asthma, migraine, gastrointestinal disorder, etc;&#xD;
&#xD;
          -  Acute febrile illness with oral temperature &gt;37.7°C or axillary temperature &gt;37.5°C on&#xD;
             the day of vaccination (refer to section 7.1 Delay/Discontinuation of Study&#xD;
             Vaccination); enrollment could be considered if the fever is absent for 72 hours;&#xD;
&#xD;
          -  Any confirmed or suspected human immunodeficiency virus (HIV) infection;&#xD;
&#xD;
          -  Children in care or under a court order;&#xD;
&#xD;
          -  According to the investigator's judgment, the subject has any other factors that might&#xD;
             interfere with the results of the clinical trial or pose additional risk to the&#xD;
             subject due to participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexis Kalergis, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Facultad de Medicina, Pontlficla Universidad Católica de Chile</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexis Kalergis, Doctor</last_name>
    <phone>56 22 686 2842</phone>
    <email>akalergis@bio.puc.cl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital de Puerto Montt</name>
      <address>
        <city>Puerto Montt</city>
        <state>Los Lagos</state>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loreto Twele, Doctor</last_name>
      <email>loreto.twele@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clínica Alemana Valdivia</name>
      <address>
        <city>Valdivia</city>
        <state>Los Ríos</state>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Calvo, Doctor</last_name>
      <email>mcalvo@uach.cl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universidad Clinico de Antofagasta</name>
      <address>
        <city>Antofagasta</city>
        <state>Metropolitana</state>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Cárdenas, Doctor</last_name>
      <email>dr_cardenas2000@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Roberto del Río</name>
      <address>
        <city>Independencia</city>
        <state>Metropolitana</state>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorena Tapia, Doctor</last_name>
      <email>loretapia@uchile.cl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clínica San Carlos de Apoquindo</name>
      <address>
        <city>Las Condes</city>
        <state>Metropolitana</state>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcela Potin, Doctor</last_name>
      <email>mpotin@ucchristus.cl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clínica Universidad de los Andes</name>
      <address>
        <city>Las Condes</city>
        <state>Metropolitana</state>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Guzmán, Doctor</last_name>
      <email>pguzmanm@clinicauandes.cl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>San Joaquín</name>
      <address>
        <city>Macul</city>
        <state>Metropolitana</state>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Macarena Goldsack, Doctor</last_name>
      <email>macarenagoldsack@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Sótero del Río</name>
      <address>
        <city>Puente Alto</city>
        <state>Metropolitana</state>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valentina Gutiérrez, Doctor</last_name>
      <email>vgutierrezu@uc.cl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Ezequial Gonzalez</name>
      <address>
        <city>San Miguel</city>
        <state>Metropolitana</state>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rodolfo Villena, Doctor</last_name>
      <email>rvillena@uchile.cl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marcoleta</name>
      <address>
        <city>Santiago</city>
        <state>Metropolitana</state>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexis akalergis@bio.puc.cl, Doctor</last_name>
      <phone>56 22 686 2842</phone>
      <email>akalergis@bio.puc.cl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clínica Alemana</name>
      <address>
        <city>Vitacura</city>
        <state>Metropolitana</state>
        <country>Chile</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrea Schilling, Doctor</last_name>
      <email>dra.andrea.schilling@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Gustavo Fricke</name>
      <address>
        <city>Viña del Mar</city>
        <state>Valparaíso</state>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcela González, Doctor</last_name>
      <email>marcegl@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 3, 2021</study_first_submitted>
  <study_first_submitted_qc>August 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2021</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

